Expedeon AG

Climate Impact & Sustainability Data (2017, 2018)

The company received shareholder approval for a share option program for the board.

High risk profile inherent in the Life Science industry.
Rapidly changing market and competitive landscape.
Risk of insufficient market demand for products.
Risk of not being able to in-license suitable projects.
Risks associated with acquiring companies (integration challenges, shareholder dilution).
Potential challenges to patent rights.
Difficulty in attracting and retaining qualified personnel.
Securing sufficient funding for growth.
Risks related to tax loss carryforwards.
Financial risks (interest rate, credit, liquidity, and currency risks).
Potential impact of Brexit on UK assets.

Strict cost control measures.
Diversification of products and distribution channels.
Thorough analysis of new projects (technical and market aspects).
Evaluation of various funding options.
Monitoring of outstanding customer invoices and payment receipt.
Long-term agreements with distributors to minimize default risks.
Continuous monitoring of environmental, health, and safety regulations.
Consultation with internal and external experts to manage legal and regulatory risks.
Creation of provisions for potential risks.
Monitoring the potential impact of Brexit.

Proportion of women in the total workforce of the Expedeon Group was 40% in 2018.

Issued declaration of compliance with the German Corporate Governance Code in accordance with Sec. 161 AktG.

Implemented stringent cost control measures.
Prepared business plan for 2019 anticipating positive EBITDA.
Created a Brexit Steering Committee to appraise developments and potential impact.
Reviewed supplier and customer relationships and built up key inventories.
Worked with logistics partners to ensure contingency plans and processes are in place.
Worked to ensure alternative supply and production routes are available.

Climate Change Data